US Patent 9,387,187: Scope, Claims, Expiration and Adapalene Patent Landscape

US Patent 9,387,187 protects a method of treating acne with once-daily topical adapalene 0.3% gel or cream when the treatment produces a statistically or clinically superior reduction in inflammatory, non-inflammatory, or total acne lesions by week four compared with vehicle or adapalene 0.1%. The patent is a method-of-use patent, not a broad composition patent.

Its commercial relevance is concentrated in adapalene 0.3% products, especially Differin 0.3% gel and any generic product whose labeling or clinical performance supports the claimed early-onset treatment method. The strongest claims are directed to the 0.3% concentration combined with the four-week comparative outcome. The narrowest claims also recite the specific Differin-type gel excipient system.

What does US Patent 9,387,187 cover?

The patent covers four related treatment concepts:

Claim group	Protected clinical outcome	Dosage form	Concentration	Comparator
Claims 1-5	Inflammatory, non-inflammatory, or total lesion regression	Gel or cream	0.3% adapalene	Vehicle or 0.1% adapalene
Claims 6-10	Inflammatory lesion regression	Gel or cream	0.3% adapalene	Vehicle or 0.1% adapalene
Claims 11-16	Non-inflammatory lesion regression	Gel or cream	0.3% adapalene	Vehicle or 0.1% adapalene
Claims 17-21	Total acne lesion regression	Gel or cream	0.3% adapalene	Vehicle or 0.1% adapalene

The patent does not claim adapalene as a chemical entity. Adapalene itself is an established retinoid active ingredient. The patent also does not claim every adapalene formulation or every use of adapalene for acne.

The protected combination is:

Common acne treatment.
Topical administration.
Daily administration.
An anti-acne effective amount.
A formulation containing 0.3% by weight adapalene or a salt.
A gel or cream vehicle.
Early onset by four weeks.
Greater lesion regression than vehicle or a comparable 0.1% adapalene formulation.

The claim language places the four-week clinical result inside the scope of the claims. That result limitation is central to both infringement and validity analysis.

How do the independent claims differ?

Claims 1, 6, 11 and 17 are the principal independent claims.

Claim 1: Broadest clinical-outcome claim

Claim 1 covers early regression of any one of three categories:

Inflammatory lesions.
Non-inflammatory lesions.
Total acne lesions.

It is the broadest independent claim because it captures any of the three specified outcomes. A product or treatment need not improve all three categories to fall within the language. Improvement in one category may satisfy the stated outcome, subject to the remaining limitations.

Claim 6: Inflammatory-lesion claim

Claim 6 is narrower in clinical scope because it is limited to regression of inflammatory lesions. It may be commercially important because inflammatory lesion reduction is a standard endpoint in acne trials and appears in product labeling and clinical evidence.

Claim 11: Non-inflammatory-lesion claim

Claim 11 covers regression of non-inflammatory lesions, including comedonal manifestations of acne. The claim uses the same 0.3% concentration, daily topical dosing, dosage-form, and four-week comparison requirements.

Claim 17: Total-lesion claim

Claim 17 covers regression of total acne lesions. It is narrower than claim 1 with respect to the specified outcome but may be easier to evaluate using aggregate lesion-count data from a clinical study.

What formulations are protected by US 9,387,187?

The patent covers 0.3% adapalene in either a gel or cream. Claims 3, 8, 13, 14 and 21 narrow the formulation to a gel containing the following ingredients:

Adapalene at 0.3% by weight.
Carbomer 940.
Disodium edetate.
Methyl paraben.
Poloxamer 124.
Propylene glycol.
Sodium hydroxide.
Purified water.

This excipient combination corresponds to a conventional adapalene 0.3% gel formulation. The dependent claims are narrower than claims 1, 6, 11 and 17 because they require the listed excipient system.

The formulation claims do not appear to require exact quantities of each excipient. They require the presence of the listed components in a gel containing 0.3% adapalene. A formulation using the same ingredients in materially different proportions may still present infringement risk, although construction would depend on the claim language, specification and prosecution history.

A product using a different gelling agent, preservative, surfactant, chelating agent or neutralizer may avoid the narrow excipient claims. That change would not necessarily avoid the broader claims, which require only a gel or cream and the claimed clinical result.

How strong are the claims from a patent-scope perspective?

The patent has moderate commercial breadth but narrower technical scope than a composition patent.

Scope factor	Assessment	Reason
Active ingredient	Narrow	Limited to adapalene and salts
Concentration	Narrow	Requires 0.3% by weight
Route	Narrow	Topical administration
Frequency	Narrow	Daily administration
Dosage form	Moderate	Gel or cream
Disease	Moderate	Common acne
Clinical endpoint	Narrow but commercially important	Improvement by four weeks
Comparator	Narrow	Vehicle or 0.1% adapalene
Excipient claims	Very narrow	Requires the listed gel components
Chemical composition protection	None	Does not claim adapalene itself

The claims can be commercially effective against a labeled 0.3% adapalene generic because the product label may instruct daily topical use for acne. The principal enforcement issue is whether the generic label, clinical data or actual use establishes the four-week superiority limitation.

A generic manufacturer may argue that the claims are not infringed unless the product produces the claimed result or the label specifically encourages the claimed method. The patent holder may respond that the four-week result is an inherent property of using the claimed 0.3% product under the recited treatment conditions.

When does US Patent 9,387,187 lose exclusivity?

The patent issued on July 12, 2016. Its expiration date should be determined from the applicable earliest effective nonprovisional filing date, adjusted for any patent-term adjustment or terminal disclaimer.

Based on the patent’s filing history and the ordinary 20-year patent term applicable to post-1995 U.S. applications, the expected statutory term falls in the 2029 period, subject to the USPTO term calculation. A pediatric extension would require a qualifying FDA determination and is not established by the claims alone.

Event	Date or status
Patent issue	July 12, 2016
Expected statutory term	Approximately 2029, subject to PTA or terminal disclaimer
FDA small-molecule exclusivity	Separate from patent term
Generic entry	Controlled by patent term, Orange Book listing, litigation and settlement terms
Biosimilar exclusivity	Not applicable

The relevant exclusivity analysis must separate:

Patent protection under US 9,387,187.
Any earlier adapalene formulation patents.
FDA marketing exclusivity for the reference product.
Other Orange Book-listed patents.
Litigation settlements or licenses.

Patent expiration does not automatically establish the earliest lawful generic launch date if other unexpired patents remain listed or enforceable.

What is the Orange Book status of the patent?

US 9,387,187 is directed to a method of treating acne with adapalene 0.3%. Method-of-use patents can be listed in the FDA Orange Book when they claim an approved use of an approved drug product and satisfy FDA listing requirements.[1]

The relevant reference product is Differin 0.3% gel, an adapalene topical product associated with Galderma. The commercial significance of US 9,387,187 therefore depends on whether the patent is listed against the relevant reference product and whether the approved labeling describes the claimed 0.3% acne treatment method.

An Orange Book listing would affect an abbreviated new drug application through the Paragraph IV certification process. A Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed can trigger a patent-infringement action and a potential 30-month stay under the Hatch-Waxman Act.[2]

The claims supplied do not establish the patent’s current Orange Book listing status, any delisting event or the identity of all patents listed against Differin 0.3% gel.

What Paragraph IV challenges and litigation risks exist?

For a generic 0.3% adapalene gel, the principal Paragraph IV positions would likely be:

Non-infringement arguments

A generic applicant could argue that:

Its labeling does not require treatment specifically intended to produce an early onset by week four.
The clinical result is not a limitation of the treatment instructions.
The product does not satisfy the comparative superiority requirement over vehicle or 0.1% adapalene.
The formulation does not contain the excipients required by claims 3, 8, 13, 14 or 21.
The product is not a cream or gel as construed under the patent.

Invalidity arguments

Potential invalidity theories include:

Anticipation by earlier clinical studies of adapalene 0.3%.
Obviousness based on known adapalene concentrations, acne treatment regimens and dose-response evidence.
Lack of written description for the full scope of the early-onset result.
Lack of enablement for all gels and creams containing 0.3% adapalene.
Indefiniteness in terms such as "early onset," "anti-acne effective amount" or "greater than."
Failure to establish a legally meaningful distinction from 0.1% adapalene or vehicle treatment.

Infringement arguments

The patent holder would likely focus on:

The generic label’s instruction to apply 0.3% adapalene daily.
The approved indication for common acne.
Clinical evidence showing lesion reduction at four weeks.
The generic’s formulation composition.
Statements in regulatory submissions or promotional materials describing faster or earlier improvement.

The clinical-result limitations create a litigation issue that would be less common in a pure formulation patent. The parties would likely dispute whether infringement is determined from the labeled method alone, from the product’s inherent properties, or from actual clinical use.

How does the patent compare with formulation and composition patents?

US 9,387,187 occupies a different position from a conventional drug-product patent.

Patent type	Typical protected subject matter	Relevance to adapalene 0.3%
Active-ingredient patent	Adapalene chemical structure	Generally expired or not controlling
Formulation patent	Gel composition, excipient ratios, stability or delivery	Can block a particular generic formulation
Method-of-use patent	Treating acne under specified clinical conditions	US 9,387,187
Manufacturing patent	Manufacturing process, particle size or crystallinity	May create separate supply-chain risk
Labeling patent	Approved indication or dosing instructions	May overlap with US 9,387,187
FDA exclusivity	Regulatory approval protection	Separate from patent rights

The patent’s broadest practical value comes from the 0.3% concentration and four-week efficacy limitation. Its narrower claims increase protection against a generic that copies the branded gel’s excipient system.

What generic entry risks exist?

The generic entry risk depends on the product design.

Generic 0.3% adapalene gel using the branded excipient system

This product faces the highest risk. It may implicate the broad gel claims and the narrow excipient claims. A Paragraph IV challenge would likely target the clinical-result limitation, obviousness, and the enforceability or scope of the formulation claims.

Generic 0.3% adapalene gel using different excipients

This product may avoid the narrow formulation claims but could still implicate claims 1, 6, 11 and 17. A different vehicle does not avoid the method claims if the product is a daily topical 0.3% adapalene gel used for common acne and produces the claimed four-week result.

Generic 0.3% adapalene cream

A cream falls within the independent claims but not necessarily the gel-specific dependent claims. It faces method-of-use risk while potentially avoiding the listed excipient claims.

Generic adapalene 0.1%

The patent is directed to 0.3% adapalene. A 0.1% product is outside the express concentration limitation, although separate patents, regulatory rights or labeling issues could apply.

Over-the-counter adapalene products

The existence of an OTC pathway does not eliminate patent risk. A nonprescription label can still direct consumers to a claimed method. The key issues would be the labeled concentration, dosage form, frequency and treatment indication.

Is there biosimilar risk?

There is no biosimilar pathway for adapalene. Adapalene is a chemically synthesized small-molecule drug, not a biologic subject to the Biologics Price Competition and Innovation Act.

The competitive threat is therefore generic, not biosimilar. Relevant FDA pathways include:

ANDA approval for a generic equivalent.
Potential 505(b)(2) applications for materially different formulations or delivery systems.
OTC regulatory pathways where applicable.

A 505(b)(2) applicant may face different patent-certification and labeling issues from a conventional ANDA applicant, particularly if it seeks a new formulation, indication or dosage form.

What geographic coverage does the patent provide?

US 9,387,187 provides protection only in the United States. It does not directly protect sales, manufacturing or use in Canada, Europe, Japan, China or other markets.

International risk must be assessed patent family by patent family. Relevant questions include:

Whether corresponding national patents issued.
Whether the claims cover 0.3% adapalene.
Whether the patents remain in force.
Whether supplementary protection or pediatric extensions apply.
Whether local regulatory exclusivity remains active.
Whether the formulation is manufactured in a country covered by a process patent.

A U.S. patent can affect imported products if the imported product is made through a patented process or is imported for a use covered by U.S. law. It does not create worldwide exclusivity for adapalene 0.3%.

What licensing and settlement issues affect the patent?

A complete commercial assessment requires review of:

Patent assignments and ownership records.
FDA Orange Book entries.
Paragraph IV litigation dockets.
Generic settlement agreements.
Authorized-generic arrangements.
Distributor and manufacturer licenses.
Any covenant not to sue.

The claims identify neither a license nor a settlement. Galderma’s commercial relationship to Differin does not, by itself, establish the existence or terms of any third-party license concerning US 9,387,187.

Revenue exposure and competitive landscape

The patent’s economic exposure is concentrated in:

Prescription or OTC adapalene 0.3% gel sales.
Generic substitution for the branded 0.3% product.
Combination acne products that use adapalene with benzoyl peroxide or other actives.
Dermatology prescribing patterns favoring stronger adapalene concentrations.
Retail and e-commerce distribution of topical acne products.

Combination products are not automatically outside the claims. A product containing 0.3% adapalene plus another active could still satisfy the adapalene, topical, daily-use, dosage-form and acne-treatment limitations. The four-week efficacy comparison would remain central.

The patent is less likely to block:

Adapalene 0.1% products.
Oral acne medicines.
Benzoyl peroxide-only products.
Tretinoin products.
Non-gel delivery systems outside the claim construction of "cream" or "gel."
Products used for indications other than common acne.

Key Takeaways

US 9,387,187 is a method-of-use patent for daily topical 0.3% adapalene treatment.
The protected result is superior regression of inflammatory, non-inflammatory or total acne lesions by week four.
The patent does not claim adapalene itself.
Gel and cream products are covered by the independent claims.
Several dependent claims target a specific gel formulation containing carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.
A generic 0.3% adapalene product using the branded formulation faces the highest risk.
A different formulation may avoid the narrow composition claims but can still face the broad method claims.
Adapalene creates generic, not biosimilar, competition.
The expected patent term falls in the 2029 period, subject to USPTO patent-term calculations.
Paragraph IV risk turns on Orange Book listing, the generic label, the four-week efficacy limitation and the validity of the claims.
The supplied claims do not establish current litigation, settlement, licensing or Orange Book status.

FAQs

Can a generic avoid US 9,387,187 by using adapalene 0.3% in a lotion?

Possibly. A lotion may avoid the express "gel or cream" limitation if it is not construed as either dosage form. The analysis would depend on the product’s physical characteristics, labeling and claim construction.

Does adding benzoyl peroxide avoid the patent?

No. A combination product containing 0.3% adapalene could still fall within the method claims if it is used daily for common acne and meets the four-week clinical-result limitation.

Does the patent cover spot treatment with adapalene 0.3%?

The claims require topical administration to an individual for treatment of common acne but do not expressly require whole-face application. Spot treatment could present risk if the other limitations are met.

Can a manufacturer sell 0.3% adapalene outside the United States?

US 9,387,187 does not directly prohibit foreign sales. Separate national patents, regulatory rights and manufacturing-process patents must be assessed in each jurisdiction.

Is 0.3% adapalene automatically infringing when used for acne?

No. The claims also require daily topical administration, a gel or cream, treatment of common acne, and the specified four-week lesion-regression comparison. Those limitations must be satisfied in addition to the concentration requirement.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2024). Manual of patent examining procedure: Patent term and patent term adjustment. U.S. Department of Commerce.
U.S. Patent No. 9,387,187. (2016). Methods for treating acne with adapalene. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2009). Differin gel 0.3% prescribing information. Galderma Laboratories, L.P.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
Australia	2003216898	⤷ Start Trial
Australia	2008203279	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,387,187

Summary for Patent: 9,387,187